Business
AstraZeneca's Pipeline Under Scrutiny
Following a failed clinical trial, AstraZeneca is facing questions about the sustainability of its high valuation. The company has long relied on consistent success to maintain its premium status among European pharma firms.
Coverage timeline — 1 article
CNBC
AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.
2026-07-11 05:00 UTC